Effects of bacillus Calmette-Guerin and interferon-α-2b on human bladder cancer in vitro

International Journal of Cancer

Volumn 71, Issue 5, 1997, Pages 851-857

  Zhang, Ye ^a   Khoo, Hoon Eng ^a   Esuvaranathan, Kesavan ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLADDER CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-6; MYCOBACTERIUM BOVIS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 0030997321     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970529)71:5<851::AID-IJC25>3.0.CO;2-9     Document Type: Article

References (29)

1. AKAZA, H., IWASAKI, A., OHTANI, M., IKEDA, N., NIIJIMA, K., TOIDA, I. and KOISO, K., Expression of antitumor response: role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. Cancer, 72, 558-563 (1993).
2. BADALAMENT, R.A., ORTOLANO, V. and BURGERS, J.K., Recurrent or aggressive bladder cancer: indications for adjutant intravesical therapy. Urol. Clin. North Amer., 19, 485-498 (1992).
3. BECICH, M.J., CARROLL, S. and RATLIFF, T.L., Internalization of bacillus Calmette-Guérin by bladder tumour cells. J. Urol., 145, 1316-1324 (1991).
4. BOHLE, A., GERDES, J., ULMER, A.J., HOFSTETTER, A.G. and FLAD, H.D., Effect of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol., 144, 53-58 (1990).
5. BOHLE, A., THANHAUSER, A., ULMER, A.J., ERNST, M., FLAD, H.D. and JOCHAM, D., Dissecting the immunobiological effects of bacillus CalmetteGuérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J. Urol., 150, 1932-1937 (1993).
6. BORDEN, E.C., GROVEMAN, D.S., NASU, T., REZNIKOFF, C. and BRYAN, G.T., Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J. Urol., 132, 800-803 (1984).
7. BROSMAN, S.A., Bacillus Calmette-Guérin immunotherapy: techniques and results. Urol. Clin. North Amer., 19, 557-564 (1992).
8. CARBALLIDO, J., MOLTO, L., MANZANO, L., OLIVIER, C., SALMERON, O. and ALVAREZ-MON, M., Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Cancer, 72, 1743-1748 (1993).
9. DE REIJKE, T.M., VOS, P.C., DE BOER, E.C., BEVERS, R.F., DE MUINCK KEIZER, W.H., KURTH, K.H. and SCHAMHART, D.H., Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guérin (BCG). Urol. Res., 21, 349-352 (1993).
10. DORR, R.T., Interferon-α in malignant and viral diseases. A review. Drugs, 45, 177-211 (1993).
11. ESUVARANATHAN, K., ALEXANDROFF, A.B., MCINTYRE M., JACKSON, A.M., PRESCOTT, S., CHISHOLM, G.D. and JAMES, K. Interleukin-6 production by bladder tumors is upregulated by BCG Immunotherapy. J. Urol., 154, 572-575 (1995).
12. GLASHAN, R.W., A randomized controlled study of intravesical alpha-2binterferon in carcinoma in situ of the bladder. J. Urol., 144, 658-661 (1990).
13. JACKSON, A.M., ALEXANDROFF, A.B., FLEMING, D., PRESCOTT, S., CHISHOLM, G.D. and JAMES, K., Bacillus Calmette-Guérin (BCG) organisms directly alter the growth of bladder tumour cells. Int. J. Oncol., 5, 697-703 (1994).
14. JACKSON, A.M., ALEXANDROFF, A.B., KELLY, R.W., SKIBINSKA, A., ESUVARANATHAN, K., PRESCOTT, S., CHISHOLM, G.D. and JAMES, K., Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin. exp. Immunol., 99, 369-375 (1995).
15. KUO, J.Y., NISHIO, Y., KANAMARU, H., OKADA, Y., KITA, M., IMANISHI, J., KISHIDA, T. and YOSHIDA, O., Impaired interferon-alpha production in whole-blood cultures from bladder cancer patients. Urol. Res., 19, 51-56 (1991).
16. LAMM, D.L., Complications of bacillus Calmette-Guérin immunotherapy. Urol. Clin. North Amer., 19, 565-572 (1992).
17. LAMM, D.L., RATLIFF, T.L., GILLEN, D. and CATALONA, W.J., Requirement of a thymus dependent immune response for BCG-mediated anti-tumour activity. J. Urol., 137, 155-158 (1987).
18. MORALES, A. and CURTIS NICKEL, J., Immunotherapy for superficial bladder cancer. Urol. Clin. North Amer., 19, 549-556 (1992).
19. MORALES, A., EIDINGER, D. and BRUCE, A.W., Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol., 16, 180-183 (1976).
20. NIELL, H.B., MAUER, A.M. and RADEMACHER, D., Cytotoxic effects of alpha- and gamma-interferon and tumor necrosis factor in human bladder tumor cell lines. Urol. Res., 22, 247-250 (1994).
21. PATARD, J.J., CHOPIN, D.K. and BOCCON GIBOD, L., Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. World J. Urol., 11, 165-168 (1993).
22. PRESCOTT, S., JAMES, K., HARGREAVE, T.B., CHISHOLM, G.D. and SMYTH, J.F., Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 147, 1636-1642 (1992).
23. RATLIFF, T.L., RITCHEY, J.K., YUAN, J.J., ANDRIOLE, G.L. and CATALONA, W.J., T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol., 150, 1018-1023 (1993).
24. SARGENT, E.R. and WILLIAMS, R.D., Immunotherapeutic alternatives in superficial bladder cancer: interferon, interleukin-2. and keyhole-limpet hemocyanin. Urol. Clin. North Amer., 19, 581-590 (1992).
25. SEN, G.C. and LENGYEL, P., Minireview. The interferon system. J. biol. Chem., 267, 5017-5020 (1992).
26. SHUAI, K., Interferon-activated sienal transduction to the nucleus. Curr. Opin. Cell Biol., 6, 253-259 (1994).
27. TACHIBANA, M., NAKAMURA, S., JITSUKAWA, S., DEGUCHI, N., BABA, S., HATA, M. and TAZAKI H., Long-term results and risk factors of tumor recurrence in patients with superficial bladder cancer who were treated by intravesical bacillus Calmette-Guérin (BCG) instillation. Nippon Hinyokika Gakkai Zasshi, 84, 656-661 (1993).
28. TORTI, F.M. and TWELVE OTHERS. Alpha-interferon in superficial bladder cancer: a Northern California oncology group study. J. clin. Oncol., 6, 476-483 (1988).
29. ZHANG, K. and KUMAR, R., Interferon-alpha inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. Biochem. biophys. Res. Comm., 200, 522-528 (1994).